Hepion Pharmaceuticals Ownership
| HEPA Stock | USD 0.80 0.00 0.000001% |
Some institutional investors establish a significant position in stocks such as Hepion Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Hepion Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Hepion |
Hepion Stock Ownership Analysis
The company recorded a loss per share of 220.0. Hepion Pharmaceuticals last dividend was issued on the 3rd of June 2019. The entity had 1:50 split on the 18th of March 2025. Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Hepion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To learn more about Hepion Pharmaceuticals call BSc BSc at 732 902 4000 or check out https://hepionpharma.com.Besides selling stocks to institutional investors, Hepion Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Hepion Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Hepion Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Hepion Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.95% of Hepion Pharmaceuticals are currently held by insiders. Unlike Hepion Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Hepion Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Hepion Pharmaceuticals' insider trades
Hepion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hepion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hepion Pharmaceuticals backward and forwards among themselves. Hepion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Hepion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 175 | |
| Sbi Securities Co Ltd | 2024-12-31 | 125 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 113 | |
| Group One Trading, Lp | 2024-12-31 | 84.0 | |
| Bank Of America Corp | 2024-12-31 | 57.0 | |
| Barclays Plc | 2024-12-31 | 16.0 | |
| Hanson Mcclain Inc | 2024-12-31 | 2.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Advisornet Financial, Inc | 2024-12-31 | 0.0 | |
| Anson Funds Management Lp | 2024-12-31 | 231.8 K | |
| Blackrock Inc | 2024-12-31 | 83 K |
Hepion Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hepion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hepion Pharmaceuticals Outstanding Bonds
Hepion Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hepion Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hepion bonds can be classified according to their maturity, which is the date when Hepion Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.